Rating Change
Barclays reiterated its Equal-Weight rating on CME Group Inc. (NASDAQ:CME) on October 07, 2026.
Barclays reiterated its Equal-Weight rating on CME Group Inc. (NASDAQ:CME) on October 07, 2026.

At publication ·
CME Group Inc. (NASDAQ:CME) · reiterate
At a glance
Barclays reiterated its Equal-Weight rating on CME Group Inc. (NASDAQ:CME) on October 07, 2026.
CME Group Inc. operates in the Financial Services sector. The stock currently trades at $270.27 with a market capitalization of $98.2B. The stock has declined 1.1% over the past 52 weeks.
Analyst coverage from Barclays provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for CME Group Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 10 most recent ratings: 5 Buy, 3 Hold, 2 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 07, 2026 | Barclays | Equal-Weight | N/A |
| Oct 05, 2026 | TD Cowen | Buy | N/A |
| Oct 05, 2026 | UBS | Neutral | N/A |
| Oct 02, 2026 | Wells Fargo | Overweight | N/A |
| Sep 28, 2026 | TD Cowen | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View CME Stock Page
A rating of Equal-Weight from Barclays reflects the analyst's outlook on CME Group Inc. (NASDAQ:CME). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the CME forecast page.
Current market data
NASDAQ · CME
$280.56
Up: +$4.12 · +1.49%
Live quote updated
Keep reading